Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/200858TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE
WO 29.09.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/IB2022/000155 Applicant SPECIFIC BIOLOGICS INC. Inventor STEAD, Brent, E.
Provided herein are compositions and methods of using chimeric nucleases comprising an I-TevI nuclease domain and a Cas domain for the targeting of oncogenes.
2.WO/2022/200663USE OF ALBUMIN FOR THE TREATMENT OF DEFECTIVE B-CELL FUNCTION
WO 29.09.2022
Int.Class A61K 38/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
38Albumins
Appl.No PCT/ES2022/070171 Applicant GRIFOLS WORLDWIDE OPERATIONS LIMITED Inventor ARROYO PEREZ, Vicente
The present invention relates to a composition comprising human albumin for regulating B-cell function in a patient suffering from systemic inflammatory response syndrome, in which the albumin is administered to the patient in a dose sufficient to increase B-cell receptor density in a B-cell population.
3.WO/2022/204173METHODS FOR PREDICTING TREATMENT OUTCOME TO CHECKPOINT INHIBITORS IN CANCER
WO 29.09.2022
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/US2022/021377 Applicant THE BRIGHAM AND WOMEN'S HOSPITAL, INC. Inventor MINEO, Marco
Described herein are methods of selecting a treatment for, and optionally treating, a subject who has a tumor and methods for determining is a subject who has a tumor is likely to benefit from an immunotherapy treatment. The methods disclosed herein can include the use of a long non-coding RNA, and/or a ribonucleoprotein, as biomarkers of patient response to immunotherapy treatment, such as an immune checkpoint inhibitor.
4.20220305078PEPTIDES AND METHODS OF USE THEREOF IN TREATING UVEITIS
US 29.09.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No 17619168 Applicant BIOMARCK PHARMACEUTICALS LTD. Inventor Indu PARIKH

The present disclosure includes methods of treating ocular inflammation or inflammatory ocular conditions, such as uveitis. More specifically the present disclosure relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present disclosure includes an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof as disclosed in the present disclosure are useful in such methods.

5.20220305142OCULAR DELIVERY OF THERAPEUTIC AGENTS
US 29.09.2022
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 17721063 Applicant Intergalactic Therapeutics, Inc. Inventor Robert FARRA

The present invention involves devices and therapies for ocular diseases or disorders in individuals. Provided herein are therapeutic agents, and devices and methods of delivering therapeutic agents (e.g., nucleic acid vectors) to target ocular cells (e.g., retinal cells) involving methods of administering therapeutic agents to the individual and methods of electrotransfer of therapeutic agents.

6.20220306696ISOLATED MODIFIED VP1 CAPSID PROTEIN OF AAV5
US 29.09.2022
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No 17637099 Applicant LIMITED LIABILITY COMPANY "ANABION" Inventor Anna Nikolaevna STRELKOVA

This application relates to the fields of gene therapy and molecular biology. More specifically, the present invention relates to an isolated altered VP1 protein of adeno-associated virus serotype 5 (AAVS) capsid comprising one or more amino acid substitutions as compared to the VP1 protein of wild-type AAVS capsid, which increase transduction efficiency, as well as to a capsid and a vector based thereon.

7.WO/2022/202239EXPRESSION ENHANCER OF MOISTURIZING FACTOR OR BARRIER FUNCTION FACTOR OF EPIDERMIS
WO 29.09.2022
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/JP2022/009603 Applicant TOYOBO CO., LTD. Inventor SUGAHARA, Tomohiro
Provided is an expression enhancer of a moisturizing factor or barrier function factor of the epidermis. The expression enhancer of a moisturizing factor or barrier function factor of the epidermis contains poly-γ-L-glutamic acid or a salt thereof.
8.WO/2022/200469A DOMINANT NEGATIVE PROTEIN OF RAD51 FOR TREATING CANCER
WO 29.09.2022
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/EP2022/057695 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor LOPEZ, Bernard
The present invention relates to the treatment of cancer In this study, the inventors decided to directly address this hypothesis and investigated the effects of RAD51 functional disruption by dominants negative like the protein SMRAD51 on tumorigenesis and tumor progression using a mouse model of breast cancer. Thus, the present invention relates to dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
9.WO/2022/198264TREATMENT OF INFLAMMATORY DISEASES
WO 29.09.2022
Int.Class A61K 31/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
Appl.No PCT/AU2022/050249 Applicant DIMERIX BIOSCIENCE PTY LTD Inventor SHEPHERD, Robert
A pharmaceutical composition comprising at least one endothelin A receptor inhibitor or a pharmaceutically acceptable salt thereof and at least one chemokine receptor 2 (CCR2) inhibitor or a pharmaceutically acceptable salt thereof.
10.WO/2022/199629GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE
WO 29.09.2022
Int.Class C07K 14/605
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
605Glucagons
Appl.No PCT/CN2022/082552 Applicant BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. Inventor YUAN, Jiandong
A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the field of medicine. The compound represented by formula I exhibits excellent GIPR and GLP-1R agonist activity and excellent pharmaceutical activity in reducing blood sugar and controlling body weight, is a therapeutic drug having a clinical application prospect, and can be used for preventing and treating diseases such as diabetes, diabetes complications, obesity, or obesity complications.